Epoetin alfa
Epogen/Procrit, Procrit, Retacrit (epoetin alfa) is a protein pharmaceutical. Epoetin alfa was first approved as Epogen/procrit on -. It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, chronic kidney failure, and neoplasms. It is known to target erythropoietin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Epogen/procrit, Procrit, Retacrit
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anemia | EFO_0004272 | D000740 | D64.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
epoetin alfa, Epogen/Procrit, Amgen, Inc. | |||
| 1997-12-31 | Orphan excl. | ||
epoetin alfa, Procrit, Amgen, Inc. | |||
| 1997-12-31 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
Clinical
Clinical Trials
524 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | 6 | 68 | 111 | 52 | 20 | 254 |
| Chronic renal insufficiency | D051436 | N18 | 4 | 7 | 19 | 6 | 8 | 44 | |
| Neoplasms | D009369 | C80 | — | 13 | 14 | 5 | 7 | 39 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 3 | 7 | 14 | 5 | 5 | 34 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 14 | 7 | 2 | — | 23 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 4 | 8 | 15 |
| Lymphoma | D008223 | C85.9 | 1 | 2 | 7 | 1 | 1 | 12 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 6 | 1 | — | 8 |
| Drug therapy | D004358 | — | 2 | 1 | 3 | — | 6 | ||
| Fatigue | D005221 | HP_0012378 | R53.83 | — | 2 | 1 | 1 | 2 | 6 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | — | 3 | 7 | — | 1 | 11 | |
| Plasma cell neoplasms | D054219 | — | 2 | 5 | — | 1 | 8 | ||
| Cerebral palsy | D002547 | G80 | 1 | 2 | 1 | — | 3 | 7 | |
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 4 | 3 | 3 | — | — | 7 |
| Blood transfusion | D001803 | — | 4 | 5 | — | 1 | 7 | ||
| Orthopedic procedures | D019637 | — | 4 | 6 | — | — | 7 | ||
| Traumatic brain injuries | D000070642 | S06 | — | 3 | 4 | — | 1 | 6 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 3 | — | 1 | 5 |
| Precancerous conditions | D011230 | — | 2 | 2 | — | — | 4 | ||
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 2 | 2 | — | — | 4 |
Show 57 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 11 | 3 | — | — | 2 | 14 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 5 | — | — | — | 5 |
| Reperfusion injury | D015427 | 1 | 1 | — | — | 1 | 3 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | — | — | 1 | 3 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | 1 | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 1 | — | — | — | 2 |
| Moyamoya disease | D009072 | EFO_0004250 | I67.5 | 1 | 1 | — | — | 1 | 2 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | — | — | — | 2 |
| Replacement arthroplasty knee | D019645 | — | 1 | — | — | 1 | 2 | ||
| Chronic disease | D002908 | — | 1 | — | — | 1 | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
| Autoimmune hepatitis | D019693 | K75.4 | 1 | — | — | — | — | 1 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
| Alveolar bone loss | D016301 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
| Iron metabolism disorders | D019189 | E83.1 | — | — | — | — | 1 | 1 | |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | — | 1 | 1 |
| Uterine diseases | D014591 | N85.9 | — | — | — | — | 1 | 1 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Myocardial reperfusion injury | D015428 | EFO_0002687 | — | — | — | — | 1 | 1 | |
| Hemiarthroplasty | D062785 | — | — | — | — | 1 | 1 | ||
| Fibrosis | D005355 | — | — | — | — | 1 | 1 | ||
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EPOETIN ALFA |
| INN | epoetin alfa |
| Description | Erythropoietin precursor (Epoetin) |
| Classification | Protein |
| Drug class | erythropoietins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 113427-24-0 |
| RxCUI | 105694 |
| ChEMBL ID | CHEMBL1201565 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00016 |
| UNII ID | 64FS3BFH5W (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Retacrit - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Procrit - Johnson & Johnson
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,147 documents
View more details
Safety
Black-box Warning
Black-box warning for: Procrit, Retacrit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45,758 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more